Ultragenyx Pharmaceutical Inc
RARE31.035USD
-10.405-25.11%
Handelsschluss 07/10, 16:00（ET）Kurse um 15 Minuten verzögert
2.91BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ultragenyx Pharmaceutical Inc Unternehmen
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Unternehmensinformationen
BörsenkürzelRARE
Name des UnternehmensUltragenyx Pharmaceutical Inc
IPO-datumJan 31, 2014
Gegründet am2011
CEODr. Emil D. Kakkis, M.D., Ph.D.
Anzahl der mitarbeiter1294
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse60 Leveroni Ct
StadtNOVATO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94949
Telefon14154838800
Websitehttps://www.ultragenyx.com/
BörsenkürzelRARE
IPO-datumJan 31, 2014
Gegründet am2011
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
15.69K
-83.00%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Dr. Deborah L. Dunsire, M.D.
Dr. Deborah L. Dunsire, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
Nach RegionUSD
Name
Umsatz
Anteil
North America
57.79M
41.49%
Latin America
54.89M
39.40%
Europe
23.33M
16.75%
Japan
3.29M
2.36%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
44.96%
Investment Advisor
27.79%
Hedge Fund
21.16%
Individual Investor
3.56%
Research Firm
1.72%
Sovereign Wealth Fund
1.02%
Private Equity
0.70%
Pension Fund
0.65%
Bank and Trust
0.28%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
627
96.81M
102.40%
-2.03M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
2023Q1
609
74.12M
105.56%
-2.85M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
9.98M
10.55%
-38.64K
-0.39%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.91M
5.2%
-49.62K
-1.00%
Mar 31, 2025
Sands Capital Management, LLC
4.16M
4.4%
-134.44K
-3.13%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.14M
3.32%
+698.80K
+28.65%
Mar 31, 2025
Kakkis (Emil D)
2.69M
2.85%
-31.78K
-1.17%
Mar 07, 2025
State Street Global Advisors (US)
2.62M
2.77%
-104.13K
-3.82%
Mar 31, 2025
Wellington Management Company, LLP
2.45M
2.59%
-8.04K
-0.33%
Mar 31, 2025
ClearBridge Investments, LLC
2.26M
2.39%
-62.50K
-2.69%
Mar 31, 2025
Adage Capital Management, L.P.
2.15M
2.27%
+965.92K
+81.64%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
2.05M
2.17%
+3.00K
+0.15%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Global X Genomics & Biotechnology ETF
3.89%
Motley Fool Small-Cap Growth ETF
3%
Motley Fool Mid-Cap Growth ETF
2.01%
Franklin Genomic Advancements ETF
2%
Virtus LifeSci Biotech Products ETF
1.84%
Touchstone Sands Capital US Select Growth ETF
1.26%
WisdomTree BioRevolution Fund
1.12%
SPDR S&P Biotech ETF
0.77%
Putnam Sustainable Future ETF
0.63%
Goldman Sachs Future Health Care Equity ETF
0.6%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil3.89%
Motley Fool Small-Cap Growth ETF
Anteil3%
Motley Fool Mid-Cap Growth ETF
Anteil2.01%
Franklin Genomic Advancements ETF
Anteil2%
Virtus LifeSci Biotech Products ETF
Anteil1.84%
Touchstone Sands Capital US Select Growth ETF
Anteil1.26%
WisdomTree BioRevolution Fund
Anteil1.12%
SPDR S&P Biotech ETF
Anteil0.77%
Putnam Sustainable Future ETF
Anteil0.63%
Goldman Sachs Future Health Care Equity ETF
Anteil0.6%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
